210 related articles for article (PubMed ID: 23783043)
1. Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.
Zhu X; Kranse R; Bul M; Bangma CH; Schröder FH; Roobol MJ
Can J Urol; 2013 Jun; 20(3):6756-60. PubMed ID: 23783043
[TBL] [Abstract][Full Text] [Related]
2. The analysis of competing events like cause-specific mortality--beware of the Kaplan-Meier method.
Verduijn M; Grootendorst DC; Dekker FW; Jager KJ; le Cessie S
Nephrol Dial Transplant; 2011 Jan; 26(1):56-61. PubMed ID: 21059831
[TBL] [Abstract][Full Text] [Related]
3. Cumulative incidence in competing risks data and competing risks regression analysis.
Kim HT
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
[TBL] [Abstract][Full Text] [Related]
4. [Mortality due to prostate cancer in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Results after a 15-year follow-up].
Luján M; Páez Á; Berenguer A; Rodríguez JA
Actas Urol Esp; 2012; 36(7):403-9. PubMed ID: 22269382
[TBL] [Abstract][Full Text] [Related]
5. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
6. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer.
Carlsson SV; Holmberg E; Moss SM; Roobol MJ; Schröder FH; Tammela TL; Aus G; Auvinen AP; Hugosson J
BJU Int; 2011 Jun; 107(12):1912-7. PubMed ID: 20950305
[TBL] [Abstract][Full Text] [Related]
7. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
8. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
9. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?
Otto SJ; Schröder FH; de Koning HJ
J Med Screen; 2004; 11(2):89-92. PubMed ID: 15153324
[TBL] [Abstract][Full Text] [Related]
10. Cause-specific mortality following radical prostatectomy.
Shikanov S; Kocherginsky M; Shalhav AL; Eggener SE
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):106-10. PubMed ID: 22083265
[TBL] [Abstract][Full Text] [Related]
11. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
[TBL] [Abstract][Full Text] [Related]
12. [Is Kaplan-Meier statistics the most appropriate tool for survivorship measurement of outcomes in orthopaedics?].
Langová K; Gallo J
Acta Chir Orthop Traumatol Cech; 2010 Apr; 77(2):118-23. PubMed ID: 20447354
[TBL] [Abstract][Full Text] [Related]
13. Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy.
Froehner M; Scholz A; Koch R; Hakenberg OW; Baretton GB; Wirth MP
Urol Int; 2012; 89(2):148-54. PubMed ID: 22813937
[TBL] [Abstract][Full Text] [Related]
14. Overestimation of the probability of death on peritoneal dialysis by the Kaplan-Meier method: advantages of a competing risks approach.
Beuscart JB; Pagniez D; Boulanger E; Lessore de Sainte Foy C; Salleron J; Frimat L; Duhamel A
BMC Nephrol; 2012 May; 13():31. PubMed ID: 22646159
[TBL] [Abstract][Full Text] [Related]
15. Competing events influence estimated survival probability: when is Kaplan-Meier analysis appropriate?
Biau DJ; Latouche A; Porcher R
Clin Orthop Relat Res; 2007 Sep; 462():229-33. PubMed ID: 17496556
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
17. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches.
Tai BC; Machin D; White I; Gebski V;
Stat Med; 2001 Mar; 20(5):661-84. PubMed ID: 11241570
[TBL] [Abstract][Full Text] [Related]
18. Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.
Taghipour S; Banjevic D; Fernandes J; Miller AB; Montgomery N; Harvey BJ; Jardine AK
Breast Cancer Res Treat; 2012 Jul; 134(2):839-51. PubMed ID: 22689090
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
